Clinical Trials Logo

Filter by:
NCT ID: NCT02551861 Withdrawn - Hepatitis C Clinical Trials

A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3

Start date: December 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if 8 weeks of Daclatasvir plus Sofosbuvir with or without Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients without advanced fibrosis or liver cirrhosis who have never been treated previously.

NCT ID: NCT02546336 Withdrawn - Chronic Pain Clinical Trials

Ultrasound-Guided Hip Joint Cooled Radiofrequency Denervation

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Hip osteoarthritis (HOA) is a common cause of pain and disability in aging population. Conservative treatment is based on lifestyle modifications, physical therapy, analgesic and anti-inflammatory medications and intra articular injections. This Prospective Pilot Study aims at investigating the efficacy of Ultrasound-Guided Cooled Radiofrequency Hip Denervation as a treatment offered to patients with HOA.

NCT ID: NCT02536092 Withdrawn - Hypertrichosis Clinical Trials

A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal

Start date: September 2015
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of the Cutera excel HR dual wavelength 755nm Alexandrite and 1064nm Nd:YAG laser for hair removal.

NCT ID: NCT02527174 Withdrawn - Clinical trials for Leukemia, Myeloid, Acute

A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia

VIAC
Start date: November 2016
Phase: Phase 1
Study type: Interventional

This is a Phase I clinical trial to determine the maximum tolerated dose (MTD) of the polo-like kinase-1 inhibitor volasertib which can be safely combined with idarubicin plus cytarabine induction chemotherapy for previously untreated patients with acute myeloid leukemia. (AML).

NCT ID: NCT02509403 Withdrawn - Clinical trials for Urinary Tract Infections

An Open-label Trial to Evaluate the Safety of an Essential Oil Infused Perineal Towel

WIPEAWAY
Start date: January 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety (absence of skin irritation) of a feminine hygiene product for perineal hygiene prior to undertaking a clinical effectiveness trial. The feminine hygiene towel or wipe is an anti-bacterial Natural Health Product solution.

NCT ID: NCT02505178 Withdrawn - Depression Clinical Trials

Examining the Feasibility and Effectiveness of Case Manager Delivered Problem Solving Therapy on Late Life Depression

Start date: August 2015
Phase: N/A
Study type: Interventional

This study seeks to determine the feasibility and efficacy of a Problem Solving Therapy intervention for the treatment of late life depression (LLD). Participants diagnosed with LLD will participate in six sessions of Problem Solving Therapy, a form of talk-therapy, over a period of eight weeks. A Case Manager (CM) will lead the PST. The primary outcome measure is depression severity and will be measured throughout the study at weeks 0, 4, and 8. the secondary outcome measure is quality of life and will be measured at week 0 (pre-intervention) and week 12.

NCT ID: NCT02497638 Withdrawn - Prostate Cancer Clinical Trials

LIpitor and biGuanide to Androgen Delay Trial

LIGAND
Start date: December 2021
Phase: Phase 2
Study type: Interventional

This study is a randomized trial examining the administration of a combination of biguanide metformin and atorvastatin ("Lipitor") to men who are experiencing rising prostate-specific antigen (PSA) levels, despite having undergone radical therapy (surgery and/or radiation).

NCT ID: NCT02490098 Withdrawn - Type 1 Diabetes Clinical Trials

Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes

Start date: January 2018
Phase: Phase 2
Study type: Interventional

Current intensive insulin therapy in T1D involves prandial insulin boluses depending on the carbohydrate content of each ingested meal. Carbohydrate content of ingested meals is the main determinant of post-meal glucose excursion. Therefore, accurate carbohydrate counting is a critical aspect of managing postprandial blood glucose levels in type 1 diabetes in order to avoid too much or too little insulin resulting in hypoglycemia and hyperglycemia, respectively. Precision of carbohydrate counting is associated with better glycemic control. However, accurate carbohydrate counting is a challenging task for many patients with type 1 diabetes. Recent developments of continuous glucose sensors and insulin infusion pumps have motivated the research toward "closed-loop'' strategies to regulate glucose levels in patients with type 1 diabetes. In a closed-loop strategy, the pump insulin infusion rate is altered based on a computer generated recommendation that rely on continuous glucose sensor readings. A dual-hormone closed-loop strategy has also been recently proposed to regulate glucose levels. In a dual-hormone strategy, subcutaneous insulin delivery is accompanied by subcutaneous glucagon infusion. Postprandial meal glucose control with closed-loop strategy still needs some improvements. The objective of this study is to test in outpatient unrestricted settings whether, in the context of closed-loop strategy, conventional meal carbohydrate counting could be reduced to a simplified qualitative meal size estimation without a significant degradation in overall glycemic control in children and adult patients with type 1 diabetes. The investigators hypothesize that 1) dual-hormone closed-loop strategy with qualitative meal size estimation is equivalent to dual-hormone closed-loop strategy with CHO counting in terms of mean glucose; 2) single-hormone closed-loop strategy with qualitative meal size estimation is equivalent to single-hormone closed-loop strategy with CHO counting in terms of mean glucose;

NCT ID: NCT02488616 Withdrawn - Type 1 Diabetes Clinical Trials

Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes

Start date: March 2018
Phase: Phase 2
Study type: Interventional

Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. The main objective of this project is to compare the efficacy of single-hormone closed-loop strategy and sensor-augmented pump therapy to regulate glucose levels in outpatient settings for 5 consecutive days in adults with type 1 diabetes. The investigators hypothesized that single-hormone closed-loop strategy will increase the time spent in the target range compared to sensor-augmented pump therapy.

NCT ID: NCT02472717 Withdrawn - Type 2 Diabetes Clinical Trials

Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

PLAQUE
Start date: May 2015
Phase: Phase 2
Study type: Interventional

Exploratory, double-blind randomized, placebo-controlled, Phase II study to evaluate the effect(s) of short-term administration of liraglutide, a GLP-1R (glucagon-like peptide-1 receptor) agonist on joint and skin inflammation in patients with active Psoriatic Arthritis.